Category Archives: UCLA

Vagal nerve stimulation for weight loss

January 22, 2015- Interviewed by Steven E. Greer, MD Erik Dutson, MD, bariatric surgeon from UCLA, discusses the newly FDA-approved weight loss device called

Posted in - Medical Devices, Bariatric surgery, Diabetes and endocrinology, Gastroenterology and liver, Primary care medicine, UCLA | Leave a comment

Current surgical weight loss therapies

January 24, 2014- Interviewed by Steven E. Greer, MD Erik Dutson, MD, weight loss surgeon at UCLA, explains why his medical center does not implant the Lap-Band,

Posted in - Medical Devices, Bariatric surgery, General surgery, UCLA | Leave a comment

Review of combination immunotherapies seen at ASCO 2016

June 22, 2016- interviewed by Steven E. Greer, MD We interviewed Siwen Hu-Lieskovan MD, PhD of UCLA, an expert with immunotherapies for melanoma,

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment

Antoni Ribas, MD discusses cancer drugs targeting the PD1 signaling pathways

March 19, 2013- Interviewed by Steven E. Greer, MD The upcoming ASCO meeting will be dominated by numerous presentations relating to new

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment

BRAF and MEK combos for melanoma

Update October 1, 2015- The FDA approved the use of two drugs, Opdivo and Yervoy, to treat metastatic melanoma, as we first discussed with Dr. Ribas last year. 

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment

CheckMate 026: Why did Opdivo (nivolumab) fail in NSCLC?

September 1, 2016- Interviewed by Steven E. Greer, MD In the wake of the news-making failure of CheckMate 026 of Bristol-Myers Squibb’s Opdivo (nivolumab) fail in

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment

Ibrance (palbociclib) to treat advanced breast cancer

November 28, 2016- Interviewed by Steven E. Greer, MD We interviewed Richard Finn, MD about his NEJM

Posted in - Biotech, - NEJM, - Pharma, Oncology, UCLA | Leave a comment

Review of immunotherapy and targeted therapy

June 17, 2016- interviewed by Steven E. Greer, MD We interviewed Siwen Hu-Lieskovan MD, PhD of UCLA, an expert with immunotherapies for melanoma, to go over the

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment

The Daltrey Townshend teenage and young adult cancer center at UCLA

May 4, 2014- Interviewed by Steven E. Greer More than 20 years ago, Roger Daltrey began forming special cancer units in the UK to treat patients in their teenage

Posted in - Opinion, Oncology, Rehab, UCLA | Leave a comment

Review of the TAVR data from the 2015 ACC

May 7, 2015- Interviewed by Steven E. Greer, MD

Posted in - Medical Devices, Cardiac surgery, Cardiology, UCLA | Leave a comment

The newly approved Edwards Lifesciences Sapien 3 aortic valve

July 5, 2015- Interviewed by Steven E. Greer, MD We interviewed William Suh, MD of UCLA about the newly approved Edwards Lifesciences Sapien

Posted in - Medical Devices, Cardiac surgery, Cardiology, FDA, UCLA | Leave a comment

Drug-coated balloons to treat fem-pop disease

April 27, 2014– Interviewed by Steven E. Greer, MD At the Charing Cross symposium in London, Medtronic reported results of the IN-PACT trial

Posted in - Medical Devices, Cardiac surgery, Cardiology, UCLA | Leave a comment

Interview with Simon Townshend about the Daltrey/Townshend Teen Cancer Program

The Daltrey Townshend teenage and young adult cancer center at UCLA

Posted in Oncology, UCLA | Leave a comment

The subcutaneous ICD

The concept of applying high voltage to shock a heart out of

Posted in - Medical Devices, Cardiac surgery, Cardiology, UCLA | Leave a comment

Robotic surgery and controversies

January 24, 2014- Dr. Dutson gives an update on the referral patterns and safety concerns over the Da Vinci system.

Posted in General surgery, UCLA | Leave a comment

New therapies for hepatitis C

November 6, 2013- Interviewed by Steven E. Greer, MD In Part 1, Sammy Saab, MD, MPH, liver disease and GI doctor from UCLA, discusses the standard of care

Posted in - Biotech, - Pharma, Gastroenterology and liver, Infectious disease, UCLA | Leave a comment

Serelaxin to treat acute heart failure

July 8, 2013- The FDA granted Novartis the coveted “Breakthrough” status for drug serelaxin

Posted in Cardiology, UCLA | Leave a comment

anti-PD1 and anti-PD-L1 drugs treating NSCLC

March 26, 2013 Interviewed By Steven E. Greer, MD

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment

New therapies for Multiple Sclerosis

Interviewed by Steven E. Greer, MD Barbara Giesser, MD, neurologist and Medical Director of the Multiple Sclerosis Center at UCLA, discusses the

Posted in Neurology, UCLA, Uncategorized | Leave a comment